Table 7.
N (%) | Treated | Median TTFT (months) | P‐value | |
---|---|---|---|---|
% of 17p – (Fig 4) | ||||
5–20% | 59 (49) | 33 | 44 | 0·002 |
20–50% | 14 (12) | 10 | 1 | |
50–65% | 15 (13) | 12 | 1 | |
65–80% | 11 (9) | 8 | 8 | |
>80% | 21 (18) | 17 | 1 | |
% of 11q – | ||||
5–20% | 13 (10) | 11 | 2 | 0·96 |
20–35% | 18 (15) | 15 | 3 | |
35–50% | 12 (10) | 8 | 3 | |
50–65% | 16 (13) | 15 | 2 | |
65–80% | 24 (19) | 21 | 3 | |
>80% | 41 (33) | 32 | 3 | |
% of trisomy 12 | ||||
1·5–15% | 23 (14) | 15 | 54 | 0·03 |
15–30% | 17 (10) | 10 | 30 | |
30–45% | 19 (12) | 14 | 15 | |
45–60% | 29 (18) | 22 | 29 | |
60–75% | 44 (27) | 34 | 7 | |
>75% | 31 (19) | 28 | 3 | |
% of 13q – (Fig 3) | ||||
7–25% | 78 (15) | 26 | Not reached | <0·0001 |
25–40% | 54 (11) | 17 | 85 | |
40–55% | 81 (16) | 31 | 89 | |
55–70% | 80 (16) | 32 | 71 | |
70–85% | 111 (22) | 53 | 52 | |
>85% | 104 (20) | 65 | 24 |
FISH, fluorescence in situ hybridization; TTFT, time to first treatment.